Prepared by: Claude Fable 5 (Anthropic) | Date: 2 Jul 2026 Patient: Alin, 82F, 58kg, Malaysian, Melbourne | GP: Dr Chitra Data reviewed: BP log 24 May–2 Jul 2026 (133 readings), pathology 30 May 2023, medication/supplement list
> Caveat: AI-generated clinical decision support to inform Dr Chitra's assessment, not a diagnosis. Verify against own examination and current Australian guidelines (RACGP/Therapeutic Guidelines).
Mild anaemia — Hb 113, PCV 0.35, RCC 3.70, with MCV 96 (top of range). This pattern in a strict Jain vegetarian suggests an early macrocytic process — B12 deficiency until proven otherwise. A crucial subtlety: combined B12 + iron deficiency produces a deceptively normal MCV (macrocytosis and microcytosis cancel out), and a Jain vegetarian is at risk of both simultaneously.
ESR 23 (ref <20). Age-adjusted upper limit for 82F is ~46. ESR 23 is normal for her age.
Vitamin D 18 nmol/L — moderate-to-severe deficiency. 1000 IU/day is a maintenance dose, not correction. From 18, standard practice is 3000–5000 IU daily for 6–12 weeks, then maintenance. After 3 years on 1000 IU she may have only reached 40–60. Vitamin D deficiency independently increases falls risk and sarcopenia.
Lipids (TC 5.4, LDL 3.5, ratio 4.5). Mildly unfavourable. At 82 with no documented CV event, statin initiation is nuanced — low priority.
Normal at the time: glucose 5.4, eGFR 81, creatinine 63, LFTs, electrolytes (K 4.6 — before daily telmisartan and banana habit).
| Test | Why | Overdue by |
|---|---|---|
| U&E + creatinine/eGFR | On an ARB; annual monitoring minimum | ~2 years |
| Potassium specifically | ARB + ~1000mg/day K from bananas + age 82 | Urgent-ish |
| FBE | Anaemia never rechecked after starting treatment | ~2.5 years |
| Ferritin/iron studies | On Maltofer with no documented baseline | Since 2023 |
| B12 (active B12/holoTC) + folate | On B12 supplement; need to confirm repletion | Never done |
| Vitamin D | Last 18 nmol/L; dose likely inadequate | 3 years |
| TSH | Anaemia + labile BP + age; thyroid mimics both | Never documented |
| HbA1c | Age 82, only single fasting glucose on record | 3 years |
| Urine ACR | Baseline for ARB/renal monitoring | Never documented |
Telmisartan (Macardis) 40mg daily. 40mg is the standard adult starting dose — but not for an 82-year-old, 58kg woman.
Is crash-rebound consistent with over-medication? Yes — but the crashes fit excess ARB effect; the rebounds to 140–156 tell you her intrinsic BP still runs high and autonomic buffering is poor. This is relative over-medication superimposed on genuinely labile hypertension — dose optimisation, not cessation.
Recommendation: reduce to telmisartan 20mg daily (preferred over 40mg EOD — EOD recreates peak-trough swing). Do not stop abruptly. Reassess with home BP after 2 weeks.
Flagged: Polaramine (dexchlorpheniramine). First-generation sedating antihistamine on the Beers Criteria as potentially inappropriate in older adults. Replace with loratadine PRN (non-sedating, BP-neutral).
Triple whammy warning: ARB + any diuretic + any NSAID = acute kidney injury risk. No Nurofen/NSAIDs without checking with Dr Chitra.
Primary: iatrogenic relative overtreatment (daily telmisartan since 24 May) acting on age-related baroreflex impairment — drug-amplified labile hypertension of the elderly.
Contributing factors, ranked: 1. Postprandial hypotension — carb-heavy Jain diet, classic trigger >80 2. Episodic dehydration — 2 coffees on Jun 21; Maltofer GI effects 3. Dietary potassium load — 2 bananas/day stacks with ARB's K retention 4. Dietary sodium swings — high-salt days (noodles + seeds) → crash within 48h 5. Orthostatic component — suspected but never actually measured
Measurement caveat: "9 sessions with 10+ point within-session drops" is mostly the first-reading effect (alerting response). The day-to-day averages (109–143, SD 10.1) are the real signal. Also: all readings are morning-only — zero afternoon/evening visibility.
Differentials to exclude: paroxysmal arrhythmia (ECG is cheap), thyroid dysfunction, autonomic failure (orthostatic test screens this).
| Nutrient | Risk | Status |
|---|---|---|
| Vitamin B12 | Near-certain without supplementation | Supplemented only ~1 month; neurological deficits lag haematological correction |
| Vitamin D | Confirmed 18 nmol/L | Under-dosed at 1000 IU — needs correction dosing |
| Iron | High (non-haem only, no alliums/vit C with meals) | On Maltofer, never verified with ferritin |
| Omega-3 (EPA/DHA) | High — zero dietary source without fish | Unsupplemented; algal-oil DHA/EPA is Jain-compatible |
| Zinc | Moderate — plant zinc poorly absorbed | Partially covered by Ensure |
| Iodine | Moderate — depends on iodised salt | Check |
| Calcium | Lower — dairy OK, Ensure fortified | Adequate if dairy intake is real |
| Protein | Addressed — ~52g/day from Ensure + whey | Likely meeting 58–70g target |
Correction: telmisartan is NOT renally excreted — >97% eliminated in bile/faeces. The classic accumulation risk does not apply.
Real renal risks: 1. Flying blind on an ARB for 2+ years. eGFR 81 in 2023, likely ~78 now without crashes. Annual U&E is minimum standard. 2. Hyperkalaemia — the most concrete danger. ARB + 2 bananas/day + age 82 + K 4.6 before both exposures. This alone justifies bloods this week. 3. Haemodynamic AKI during crashes. ARBs disable kidney autoregulation. Each hypotensive day is a small renal insult. 4. Triple whammy if NSAID ever added.
Risk: moderate and preventable — but currently unmonitored.
This week (before any medication change): 1. Pathology: U&E/creatinine/eGFR, FBE, ferritin + iron studies, active B12 + folate, vitamin D, TSH, HbA1c, fasting lipids, urine ACR 2. Orthostatic BP: supine → standing at 1 and 3 minutes
Next visit (with bloods back): 3. Reduce telmisartan to 20mg daily — 2-week home-BP trial; target avg ~130–145 with zero symptomatic days 4. Swap Polaramine → loratadine PRN (Beers criteria) 5. Vitamin D correction: 3000–5000 IU/day for 6–12 weeks, then recheck 6. If anaemia persists: escalate — occult GI blood loss (FOBT), coeliac serology, myeloma screen 7. Consider 24h ABPM — all data is morning-only; nocturnal/postprandial profiles unknown 8. ECG — exclude arrhythmia given IHB flags and pulse trending to 68–69
Red flags for family: SYS <100 or symptomatic dizziness → sit/lie down, fluids, call practice; pulse <60; any faint/fall → same-day review; black/tarry stools; no NSAIDs without asking.
Rating: HIGH — the organising clinical concern.
Stacked risk factors: age 82; documented symptomatic hypotensive episodes; 34% days in hypotensive range; probable orthostatic hypotension; vitamin D 18; possible B12 deficiency (proprioceptive/neuropathic effects lag repletion); Beers-criteria antihistamine; sarcopenia risk. One fall with hip fracture at 82 carries ~20–30% one-year mortality.
Actions:
Bottom line for Dr Chitra: An 82-year-old with well-controlled average BP but symptomatic instability that began when telmisartan went from alternate-day to daily, monitored on 3-year-old bloods, with a live hyperkalaemia question, anaemia never verified, under-dosed vitamin D, and a Beers-list antihistamine — in a patient whose dominant risk is a fall. Bloods this week, orthostatic BP in clinic, then a telmisartan dose reduction trial. Nothing here is an emergency; all of it is fixable.